MicroRNA miR-145-5p regulates cell proliferation and cell migration in colon cancer by inhibiting chemokine (C-X-C motif) ligand 1 and integrin α2

Wei Zhuang, Tao Niu, and Zhen Li
Department of Gastroenterology, People’s Hospital of Dongxihu District, Wuhan, Hubei, China

ABSTRACT
Colon cancer (CC), which has high morbidity and mortality, can be regulated by microRNAs. This study aimed to investigate the regulatory function of microRNA miR-145-5p in CC cells. Bioinformatics analysis was used to screen key genes in CC. The expression of miR-145-5p, chemokine (C-X-C motif) ligand 1 (CXCL1), and integrin α2 (ITGA2) in CC was confirmed by quantitative reverse transcription polymerase chain reaction and western blotting. After cell transfection, changes in proliferation and migration in CC cells were detected using the cell counting kit-8 (CCK-8), colony formation assay, and wound healing assay. A luciferase assay was conducted to confirm the interactome of miR-145-5p, CXCL1, and ITGA2 in CC cells. Bioinformatics analysis confirmed that CXCL1 and ITGA2 were key genes in CC. After performing several cell functional experiments, the results confirmed that upregulation of miR-145-5p attenuated proliferation and migration of CC cells. Luciferase assay and western blotting confirmed that CXCL1 and ITGA2 were targets of miR-145-5p, and their expression in CC could be suppressed by miR-145-5p. In conclusion, miR-145-5p is a tumor suppressor in CC and can inhibit the expression of CXCL1 and ITGA2.

Introduction
Colon cancer (CC), with high morbidity and mortality rates, is widely distributed worldwide [1,2]. In China, people with CC tend to be younger due to changes in lifestyle and diet [3]. Despite major advances in therapeutic strategies, including chemotherapy, surgical resection, and radiotherapy, it has been suggested that the number of patients with CC will increase by 60% worldwide by 2030 [4]. Therefore, identification of novel molecular markers is necessary for CC therapy.

MicroRNAs (miRNAs) of ~22 bp are common non-coding RNAs that often participate in the progression of human cancers [5]. miRNAs are regulated by competitive endogenous RNA (ceRNA) [6]. The ceRNA mechanism identifies specific miRNA-binding sites on the target genes of miRNAs, thereby regulating the expression of target genes [6]. miR-145-5p, a member of the p53-tumor suppressor network, acts as a post-transcriptional regulator of many cancer-related genes [7]. Previous studies have reported that miR-145-5p is a suppressor in breast cancer by regulating SOX2 [8], gastric cancer by regulating KLF5 [9], and bladder cancer by regulating TAGLN2 [10]. However, the downstream role of miR-145-5p in key target genes has not been fully explored. Here, we investigated the effect of miR-145-5p on CC in vitro, which was shown to inhibit angiogenesis in CC by regulating the EGFR-associated signaling pathway [11].

Chemokine (C-X-C motif) ligand 1 (CXCL1), a member of the G protein-coupled receptor family, is overexpressed in colorectal cancer to facilitate metastasis and progression [12,13]. Integrin α2 (ITGA2) is highly expressed in multiple cancers to regulate tumorigenesis [14–16]. In colorectal cancer, ITGA2 was also shown to be an oncogene that was targeted by miR-16-5p [17]. However, the regulatory mechanism upstream of CXCL1 and ITGA2 in CC is still not explored.

According to a previous study and bioinformatics analysis, we suspected that miR-145-5p might regulate CC progression by targeting...
CXCL1 and ITGA2. Hence, this study aimed to investigate the interaction among miR-145-5p, CXCL1, and ITGA2 in CC progression using cell functional experiments. Our findings may provide potential molecular markers for CC therapy.

**Materials and methods**

**Bioinformatics analysis**

GEPIA is a database that includes differentially expressed genes in CC samples, and GSE126095 is a microarray that includes the expression of genes and miRNAs in CC samples. Genes upregulated in CC, with adjusted \( p < 0.05 \) and \( \log FC > 2 \) values, were screened using GEPIA and GSE126095. STRING was then applied to GO enrichment. Finally, TargetScan was used to predict the miRNAs targeting the key genes. At the same time, the downregulated miRNAs in CC samples were screened using GSE126095 with adjusted \( p < 0.05 \) and \( \log FC < -1 \).

**Clinical sample collection and cell culture**

The use of CC tissues and adjacent normal tissues from 36 patients diagnosed with CC in our hospital between April 2019 and November 2020 was approved by the ethics committee of the People’s Hospital of Dongxihu District. All volunteers signed an informed consent statement, and their clinical characteristics are listed in Supplementary Table 1.

All cell lines used in this study, including CC cell lines (SW620, SW480, and HCT116) and the human normal colon cell line FHC, were obtained from BeNa Culture Collection (China). The SW480 cell line was incubated in DMEM, whereas the other cell lines were incubated in RPMI-1640 medium. All media were supplemented with 10% FBS, and the cells were incubated at 37°C with 5% CO₂.

**Cell transfection**

We transfected \( 1 \times 10^5 \)/mL SW620 and HCT116 cells with miR-145-5p mimic (miR20000437-1-5, RiboBio, China), mimic-NC (miR20000437-1-5, RiboBio, China), miR-145-5p inhibitor (miR20000437-1-5, RiboBio, China), and inhibitor-NC (miR20000437-1-5, RiboBio, China) at a final concentration of 50 nM using Lipofectamine 2000 (Thermo Fisher Scientific, Inc., USA). Cell transfection was performed at 37°C with 5% CO₂ and maintained for 48 h for subsequent experiments.

**Quantitative reverse transcription polymerase chain reaction (qRT-PCR)**

RNA extraction was conducted using TRIzol reagent (Invitrogen, USA), and RNA reverse transcription was performed using the PrimScript RT reagent Kit (Takara, Japan). After transcription, qRT-PCR was performed using the Applied Biosystems StepOne System (Applied Biosystems, USA). The \( 2^{-\Delta \Delta Ct} \) method [18] was used to analyze the expression of miRNAs and mRNAs. The mRNA expression was normalized to that of GAPDH, and miRNA expression was normalized to U6. The primer sequences used are listed in Supplementary Table 2.

**Cell proliferation detection**

The change in cell proliferation was evaluated using the cell counting-8 kit (CCK-8) and colony formation assays, as described previously [19,20]. In the CCK8 assay, CC cells in the logarithmic growth phase were seeded in 96-well plates at a density of 5,000 cells/well. After transfecting cells for 0, 24, 48, and 72 h, serum-free medium with 10 μl of CCK-8 solution (Beyotime, China) was added to each well and incubated for 4 h at 5% CO₂ and 37°C. Finally, the absorbance of each well was measured to evaluate the cell proliferation ability using a microplate reader at 450 nm.

For the colony formation assay, cells were digested with trypsin after transfection, and 1,000 cells were seeded into six-well plates and incubated at 37°C with 5% CO₂. Cell transfection plasmids were added to the cells every 48 h. After 15 days, colonies were stained using 0.1% crystal violet and photographed using an optical microscope to count the number of colonies.

**Cell migration detection**

Cell migration ability was detected using a wound healing assay, according to a previous study [21].
CC cells were seeded in six-well plates and cultured until ~100% confluence. Then, the cells were scratched using a 200 μl sterile pipette tip, and PBS was used to remove the exfoliated cells. Next, the cells were incubated for 24 h in a serum-free medium. The wound at 0 and 24 h was photographed using an optical microscope to determine the cell migration rate.

Luciferase assay

The wild-type (WT) CXCL1 3’UTR and ITGA2 3’UTR containing the binding sites for miR-145-5p were synthesized and inserted into the pGL3 vectors (Promega, USA). The mutant (MUT) CXCL1 3’UTR and ITGA2 3’UTR mutated from WT by site-directed mutagenesis were also inserted into the pGL3 vectors. Then, the WT or MUT CXCL1 vectors and WT or MUT ITGA2 vectors were co-transfected with miR-145-5p mimic or mimic-NC into colon cells. After 48 h of co-transfection, the Dual-Luciferase Reporter Assay Kit (Promega) was used to verify firefly luciferase activity and Renilla luciferase activity [19].

Western blotting

Western blotting was performed as previously described [21]. Total proteins from colon cells were isolated using RIPA lysis buffer (Sigma, USA), and the concentration of isolated proteins was confirmed using a BCA assay kit (Pierce, USA). Then, 20 μg protein was separated using 15% SDS-PAGE gel for CXCL1 protein and 8% SDS-PAGE gel for ITGA2 protein and transferred to PVDF membranes. Next, the membranes were blocked with 5% nonfat milk, and the membranes were incubated overnight at 4°C with the following primary antibodies: CXCL1 (ab206411, Abcam, USA), ITGA2 (ab133557, Abcam, USA), and GAPDH (ab9485, Abcam, USA). Subsequently, the membranes were incubated with the rabbit secondary antibody (ab205718, Abcam, USA) for 3 h at 22–25°C. After washing, the membranes were incubated with an enhanced chemiluminescence kit (Pierce, USA) and placed in an X-ray film cassette. Finally, the X-ray film was placed over the membranes and exposed to visualize the protein signal. The intensity of the bands was quantified using AlphaEase FC version 6.0.2 (Alpha Innotech, USA).

Statistical analysis

Bioinformatics data were analyzed using GEO2R. The experimental data in this study are shown as mean ± standard deviation from three independent experiments, and the data were analyzed using GraphPad Prism 7.0 (GraphPad Software, Inc., USA). Student’s t-test was performed to analyze differences between two groups, whereas one-way analysis of variance (ANOVA) was conducted to analyze differences among multiple groups. Statistical significance was set at p < 0.05.

Results

Using bioinformatics analysis, we suspected that miR-145-5p might act as a key microRNA that participates in CC progression by targeting CXCL1 and ITGA2. To further explore our hypothesis, a series of cytological experiments were performed. Our results showed that miR-145-5p attenuated cell proliferation and migration in CC cells, and targeted CXCL1 and ITGA2 in CC cells. Our findings enrich the mechanism of CC progression and may provide molecular markers for CC therapy.

miR-145-5p might target CXCL1 and ITGA2 to play the key role in CC

A total of 128 upregulated genes in CC samples were screened using GEPIA and GSE126095, which had two mRNA expression profiles with adjusted p < 0.05, and logFC > 2 (Figure 1(a)). After GO enrichment by STRING, it was found that CDK1, CXCL1, and ITGA2 were related to cell proliferation and migration (Figure 1(b)). CXCL1 and ITGA2 caught our attention, since there were many studies on CDK1 in CC [22–24]. TargetScan was then used to predict the miRNAs that could target CXCL1 and ITGA2, and GSE126095, including the microRNA expression profile, was used to screen out the downregulated miRNAs with adjusted p < 0.05, and logFC < −1. As shown in Figure 1(c), only one miRNA (miR-145-5p) overlapped.
miR-148-5p could target CXCL1 and ITGA2

The binding sites of CXCL1 3’UTR and ITGA2 3’UTR for miR-145-5p were predicted using TargetScan (Figure 3(a)). Based on the predicted binding sites, we constructed WT CXCL1 or ITGA2 and MUT CXCL1 or ITGA2 vectors to perform a luciferase assay. The results showed that miR-145-5p overexpression reduced the luciferase activities in the WT CXCL1 or ITGA2 groups, but the suppression effect of miR-145-5p mimic on luciferase activity was not observed in the MUT CXCL1 or ITGA2 groups (Figures 3(b,c)).

miR-148-5p inhibited proliferation and migration of CC cells

To verify the function of miR-145-5p in CC cells, qRT-PCR was performed to confirm miR-148-5p expression in CC tissues and cells. The results showed that miR-148-5p expression was reduced by 60% in CC tissues (Figure 2(a)), and also in CC cells, including SW620, SW480, and HCT116 (Figure 2(b)). Because of similar miR-148-5p expression in SW620 and SW480 cells, we selected SW620 and HCT116 cell lines to assess the function of miR-148-5p. Then, using miR-148-5p mimic and miR-148-5p inhibitor to transfect SW620 and HCT116, the miR-148-5p expression increased by more than 10-fold in the miR-148-5p mimic group and decreased by approximately 70% in the miR-148-5p inhibitor group (Figure 2(c)). Next, CCK8 and colony formation assays were conducted to evaluate changes in cell proliferation, and we found that miR-148-5p overexpression attenuated cell proliferation and miR-148-5p knockdown facilitated cell proliferation (Figures 2(d,e)). The wound healing assay confirmed that miR-148-5p overexpression impaired the migration capability, and miR-148-5p knockdown enhanced the migration capability in vitro (figure 2(f)).

miR-148-5p inhibited the expression of CXCL1 and ITGA2

To further analyze the correlation among miR-148-5p, CXCL1, and ITGA2, we detected the expression of CXCL1 and ITGA2 in CC tissues by qRT-PCR. The results indicated that both CXCL1 and ITGA2 were upregulated by four-fold and 3.5-fold, respectively, in CC tissues (Figure 4(a)). Pearson correlation analysis showed that miR-148-5p expression was negatively correlated with the expression of CXCL1 and ITGA2 in CC tissues (Figure 4(b)). After transfecting the
Figure 2. miR-145-5p inhibited proliferation and migration of colon cancer cells. (a) qRT-PCR detected the miR-145-5p expression in adjacent normal tissues and colon cancer tissues. (b) qRT-PCR detected the miR-145-5p expression in human normal colon cell line FHC and colon cancer cell lines (SW620, SW480 and HCT116). (c) The transfection efficiency of miR-145-5p mimic and miR-145-5p inhibitor in SW620 and HCT116 was detected by qRT-PCR. (d-e) The effect of miR-145-5p on cell proliferation was assessed by CCK-8 assay (d) and colony formation assay (e). (f) The effect of miR-145-5p on cell migration was assessed by wound healing assay. NC, negative control. Mimic, miR-145-5p mimic. Inhibitor, miR-145-5p inhibitor. **P < 0.001.
miR-148-5p mimic into SW620 and HCT116 cells, it was found that the expression of CXCL1 and ITGA2 was reduced in the miR-148-5p mimic group (Figure 4(c)). Western blotting also showed that the protein levels of CXCL1 and ITGA2 were reduced by >50% in SW620 and HCT116 cells with miR-148-5p mimic transfection (Figure 4(d)).

Discussion

CC is an aggressive cancer with high morbidity and mortality rates. Here, we investigated the function of the interactome among miR-145-5p, CXCL1, and ITGA2 in CC. Our study revealed that miR-145-5p expression was reduced in CC, and miR-145-5p inhibited cell proliferation and migration in CC cells. Moreover, we confirmed that CXCL1 and ITGA2 were the target genes of miR-145-5p in CC. Our data indicated that miR-145-5p affected CC progression in vitro by inhibiting the two oncogenes CXCL1 and ITGA2.

miRNAs have been reported to inhibit the expression of mRNAs by binding to the 3’UTR of target genes, thereby participating in multiple biological processes [25–27]. miR-145-5p, a member of the miRNA family, has been proven to be a tumor suppressor in human cancers such as glioma [28], breast cancer [8], and bladder cancer [10]. In colorectal cancer, Chen et al. identified that miR-145-5p expression was downregulated and miR-145-5p mimic suppressed cell viability, migration, invasion, and epithelial–mesenchymal transition [29]. With respect to CC, only one team from Thuringer et al. [30] explored the function of miR-145-5p in angiogenesis, indicating the inhibitory effect of miR-145-5p on CC. Together with results of the previous study, we further confirmed the role of miR-145-5p in CC using cell functional experiments. Our results
were similar to those of previous studies, which showed that miR-145-5p inhibited CC progression by inhibiting proliferation and migration. Furthermore, we demonstrated for the first time that CXCL1 and ITGA2 are the target genes of miR-145-5p in CC cells, suggesting that miR-145-5p affects the malignancy of CC cells by downregulating the levels of CXCL1 and ITGA2.

Figure 4. miR-145-5p inhibited the expression of CXCL1 and ITGA2 in colon cancer. (a) The expression of CXCL1 and ITGA2 in adjacent normal tissues and colon cancer tissues was detected by qRT-PCR. (b) The correlation between CXCL1/ITGA2 and miR-145-5p was analyzed by Pearson correlation analysis. (c) The mRNA expression of CXCL1 and ITGA2 in SW620 and HCT116 cells with miR-145-5p mimic was detected by qRT-PCR. (d) The protein expression of CXCL1 and ITGA2 in SW620 and HCT116 cells with miR-145-5p mimic was detected by western blotting. NC, negative control. Mimic, miR-145-5p mimic. **P < 0.001.
Because miRNAs play a regulatory role in cancer progression by targeting oncogenes or tumor suppressor genes, we explored the downstream role of miR-145-5p in CC by examining its target genes. Together with bioinformatics analysis and a luciferase assay, CXCL1 and ITGA2 were confirmed as targets of miR-145-5p. Previous studies have shown that CXCL1 is an oncogene in colorectal cancer by enhancing metastatic ability and epithelial-to-mesenchymal transition [12,13,31]. ITGA2 also acts as an oncogene in CC by enhancing proliferation, chemotaxis, and metastasis [32,33]. Here, we explored processes upstream of CXCL1 and ITGA2, and found that miR-145-5p is a common miRNA to regulate the expression of CXCL1 and ITGA2 in CC cells. This was a novel finding.

Our study confirmed the mechanism of action of miR-145-5p in CC by targeting CXCL1 and ITGA2. However, the upstream processes of miR-145-5p involving IncRNAs or circRNAs and the downstream processes of CXCL1 and ITGA2 involving key signaling pathways have not been elucidated and need to be further investigated. In addition, the effect of the interactome among miR-145-5p, CXCL1, and ITGA2 on CC needs to be confirmed in vivo.

**Conclusion**

In conclusion, overall, our study revealed that miR-145-5p was downregulated in CC, and miR-145-5p inhibited cell proliferation and migration in CC cells. Notably, our study is the first to reveal that miR-145-5p regulates CC progression in vitro by targeting CXCL1 and ITGA2. These findings may provide novel insights into the therapy of CC.

** Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

The present study was approved by the Ethics Committee of People’s Hospital of Dongxihu District. The samples from patients were used in accordance with the principles stated in the the Declaration of Helsinki. All patients signed written informed consent.

**Patient consent for publication**

Consent for publication was obtained from the participants.

**Disclosure statement**

No potential conflict of interest was reported by the author(s).

**Funding**

The author(s) reported there is no funding associated with the work featured in this article.

**Authors’ contributions**

WZ designed this study, carried out the experiments, wrote, and drafted the manuscript; TN analyzed and interpreted the data; ZL reviewed and edited the manuscript.

**References**

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

[2] Favoriti P, Carbone G, Greco M, et al. Worldwide burden of colorectal cancer: a review. Updates Surg. 2016;68(1):7–11.

[3] Zheng R, Zeng H, Zhang S, et al. Estimates of cancer incidence and mortality in China, 2013. Chin J Cancer. 2017;36(1):66.

[4] Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–691.

[5] Xue M, Zhuo Y, Shan B. MicroRNAs, long noncoding RNAs, and their functions in human disease. Methods Mol Biol. 2017;1617:1–25.
[6] Salmena L, Poliseno L, Tay Y, et al. A ceRNA hypothesis: the rosetta stone of a hidden RNA language? Cell. 2011;146(3):353–358.

[7] Goto Y, Kurozumi A, Arai T, et al. Impact of novel miR-145-3p regulatory networks on survival in patients with castration-resistant prostate cancer. Br J Cancer. 2017;117(3):409–420.

[8] Tang W, Zhang X, Tan W, et al. miR-145-5p suppresses breast cancer progression by inhibiting SOX2. J Surg Res. 2019;236:278–287.

[9] Zhou T, Chen S, Mao X. miR-145-5p affects the differentiation of gastric cancer by targeting KLF5 directly. J Cell Physiol. 2019;234(5):7634–7644.

[10] Zhang H, Jiang M, Liu Q, et al. miR-145-5p inhibits the proliferation and migration of bladder cancer cells by targeting TAGLN2. Oncol Lett. 2018;16(5):6355–6360.

[11] Niu Y, Zhang J, Tong Y, et al. miR-145-5p restrained cell growth, invasion, migration and tumorigenesis via modulating RHBDD1 in colorectal cancer via the EGFR-associated signaling pathway. Int J Biochem Cell Biol. 2019;117:105641.

[12] Divella R, Daniele RDEL, et al. Circulating levels of VEGF and CXCL1 are predictive of metastatic organotropism in patients with colorectal cancer. Anticancer Res. 2017;37(9):4867–4871.

[13] Zhuo C, Wu X, Li J, et al. Chemokine (C-X-C motif) ligand 1 is associated with tumor progression and poor prognosis in patients with colorectal cancer. Biosci Rep. 2018;38(4):BSR20180580.

[14] Ma L, Sun Y, Li D, et al. Overexpressed ITGA2 contributes to paclitaxel resistance by ovarian cancer cells through the activation of the AKT/FoxO1 pathway. Aging (Albany NY). 2020;12(6):5336–5351.

[15] Ren D, Zhao J, Sun Y, et al. Overexpressed ITGA2 promotes malignant tumor aggression by up-regulating PD-L1 expression through the activation of the STAT3 signaling pathway. J Exp Clin Cancer Res. 2019;38(1):485.

[16] Chuang YC, Wu HY, Lin YL, et al. Blockade of ITGA2 induces apoptosis and inhibits cell migration in gastric cancer. Biol Proced Online. 2018;20:10.

[17] Xu Y, Shen L, Li F, et al. microRNA-16-5p-containing exosomes derived from bone marrow-derived mesenchymal stem cells inhibit proliferation, migration, and invasion, while promoting apoptosis of colorectal cancer cells by downregulating ITGA2. J Cell Physiol. 2019;234(11):21380–21394.

[18] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25(4):402–408.

[19] Fang F, Cheng L, Wu X, et al. miR-141 promotes colon cancer cell proliferation by targeted PHLP2 expression inhibition. Cancer Manag Res. 2020;12:11 341–11350.

[20] Zeng M, Zhu L, Li L, et al. miR-378 suppresses the proliferation, migration and invasion of colon cancer cells by inhibiting SDAD1. Cell Mol Biol Lett. 2017;22:12.

[21] Han B, Ge Y, Cui J, et al. Down-regulation of lncRNA DNAJC3-AS1 inhibits colon cancer via regulating miR-214-3p/LIVIN axis. Bioengineered. 2020;11(1):524–535.

[22] Lee DE, Lee KW, Jung SK, et al. 6,7,48-trihydroxyisoflavone inhibits HCT-116 human colon cancer cell proliferation by targeting CDK1 and CDK2. Carcinogenesis. 2011;32(4):629–635.

[23] Bury M, Le Calve B, Lessard F, et al. NFE2L3 controls colon cancer cell growth through regulation of DUX4, a CDK1 Inhibitor. Cell Rep. 2019;29(6):1469–81 e9.

[24] Yang J, Xu WW, Hong P, et al. Adefovir dipivoxil sensitizes colon cancer cells to vemurafenib by disrupting the KCTD12-CDK1 interaction. Cancer Lett. 2019;451:79–91.

[25] Zhang Z, Li J, Huang Y, et al. Upregulated miR-1258 regulates cell cycle and inhibits cell proliferation by directly targeting E2F8 in CRC. Cell Prolif. 2018;51(6):e12505.

[26] Gu M, Wang J, Wang Y, et al. MiR-147b inhibits cell viability and promotes apoptosis of rat H9c2 cardiomyocytes via down-regulating KLF13 expression. Acta Biochim Biophys Sin (Shanghai). 2018;50(3):288–297.

[27] Zhao W, Geng D, Li S, et al. LncRNA HOTAIR influences cell growth, migration, invasion, and apoptosis via the miR-20a-5p/HMG2 axis in breast cancer. Cancer Med. 2018;7(3):842–855.

[28] Chen J, Chen T, Zhu Y, et al. circPTN sponges miR-145-5p/miR-330-5p to promote proliferation and stemness in glioma. J Exp Clin Cancer Res. 2019;38(1):398.

[29] Chen Q, Zhou L, Ye X, et al. miR-145-5p suppresses proliferation, metastasis and EMT of colorectal cancer by targeting CDCA3. Pathol Res Pract. 2020;216(4):152872.

[30] Thuringer D, Jego G, Berthenet K, et al. Gap junction-mediated transfer of miR-145-5p from microvascular endothelial cells to colon cancer cells inhibits angiogenesis. Oncotarget. 2016;7(19):28160–28168.

[31] Huo WL, Chen YJ, Chang WA, et al. Interaction between tumor-associated dendritic cells and colon cancer cells contributes to tumor progression via CXCL1. Int J Mol Sci. 2018;19:8.

[32] Ruan Z, Deng H, Liang M, et al. Overexpression of long non-coding RNA00355 enhances proliferation, chemotaxis, and metastasis in colon cancer via promoting GTF2B-mediated ITGA2. Transl Oncol. 2021;14(1):100947.

[33] Ferraro A, Boni T, Pintzas A. EZH2 regulates cofillin activity and colon cancer cell migration by targeting ITGA2 gene. Plos One. 2014;9(12):e115276.